ESCONDIDO, Calif., Sept. 17, 2020 /PRNewswire/ — MARIJUANA COMPANY OF AMERICA INC. (“MCOA” or the “Company“) (OTCQB: MCOA), an innovative hemp and cannabis corporation, announced today the execution of a strategic partnership with its wholly-owned subsidiary hempSMART™ and GLO-Collective IQ (“GLO-CIQ”). GLO- CIQ is a proven result-oriented marketing agency based in Dallas, Texas with over 25 years of experience in developing and implementing award winning Network Marketing and Direct to Consumer strategies in the marketplace.
Gloria Albarran Lynch, Chief Marketing Officer of hempSMART commented, “We look forward to working with GLO- CIQ to assist hempSMART in reaching our goals and objectives.”
According to Jesus Quintero CEO, “We anticipate a rollout with our new initiatives over the next 90 days in order to position the Company for the upcoming holiday season. We look forward to our anticipated rollout of our products with the assistance of GLO- CIQ as we bring to market our enhanced products with new holiday flavors, creative new packaging, and a revamped new website.”
For more information please visit www.marijuanacompanyofamerica.com
About Marijuana Company of America, Inc.
MCOA is a corporation that participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.
About our hempSMART Products Containing CBD
The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is effective treatment for any medical condition as drugs or dietary supplements subject to the FDA’s jurisdiction.
Forward Looking Statements
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.